Xevinapant

3 trials

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

3 Sponsors

15 Countries

Phase III

Phase II

Phase III: 2 Phase II: 1

Oversight events:

9 temporary halts 1 urgent safety measure across 3 trials

View oversight register →

Indications tested

Head and neck cancer 1 Squamous cell carcinoma of head and neck 1

Sponsors using this IMP

European Organisation For Research And Treatment Of Cancer 1 Groupe Oncologie Radiotherapie Tete Cou 1 Merck Healthcare KGaA 1

All trials

3 total

Study comparing radiotherapy combined with cetuximab + Xevinapant (study drug) with radiotherapy combined with cetuximab + placebo in patien… Ended

2022-502584-38-00 Phase III 1 country Groupe Oncologie Radiotherapie Tete Cou
Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer Ended

2022-502339-20-00 Phase II 9 countries European Organisation For Research And Treatment Of Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION) Ended

2023-508528-36-00 Phase III 12 countries Merck Healthcare KGaA

Showing 1–3 of 3 trials

← All drugs A–Z